Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism
The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Abstract
CONTEXT: Primary aldosteronism (PA) represents the most frequent cause of secondary arterial hypertension. Conflicting data have been published regarding the effect of aldosterone excess on glucose metabolism. OBJECTIVE: Our aim was to analyze insulin sensitivity and β-cell function in a cohort of PA patients. Prospective follow-up investigations were performed in a subgroup of patients before and after adrenalectomy to assess the metabolic outcome. DESIGN: Oral glucose tolerance test, combined intravenous glucose tolerance test, hyperinsulinemic-euglycemic glucose clamp test, and arginine test were carried out after a 12-hour fasting period. PATIENTS: Twenty-two consecutive patients with both unilateral aldosterone-producing adenoma and bilateral idiopathic adrenal hyperplasia were recruited through the Munich center of the German Conn's Registry. The control group of patients with essential hypertension (n = 11) of corresponding age and body mass index was recruited from our hypertension unit. A normotensive cohort (n = 11) served as a further control group. RESULTS: At baseline, first-phase insulin reaction in intravenous glucose tolerance test was significantly reduced in patients with PA as compared to normal controls (36.0 [24.0; 58.7] vs 90.1 [52.6; 143.8] μU/mL, P = .031) and lower in comparison to essential hypertension without reaching statistical significance (53.2 [30.8; 73.3] μU/mL, P = .123). The study was repeated 6 months after unilateral adrenalectomy in 9 consecutive patients with aldosterone-producing adenoma. At this time point, blood pressure had been normalized in most of the patients while body mass index remained unchanged (26.9 [25.5; 37.6] vs 27.5 [25.1; 35.6] kg/m(2), P = .401). First-phase insulin reaction in response to glucose significantly increased at follow-up (from 36.0 [25.5; 58.7] to 48.5 [40.4; 95.2] μU/mL, P = .038, n = 9). In contrast, insulin sensitivity and response to iv arginine did not differ before and after adrenalectomy. CONCLUSION: Aldosterone excess has a direct negative effect on β-cell function in patients with PA. After adrenalectomy, glucose-induced first-phase insulin secretion improves significantly in the patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with aldosterone-producing adenomas, insulin secretion and disposition index assessed with intravenous glucose tolerance tests increase after adrenalectomy”
From Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans (2020) · cites this paper as [9]
In the citing paper
“Our finding of decreased insulin secretion in primary aldosteronism is consistent with a prior study which used a combined intravenous glucose tolerance test-hyperinsulinemic clamp to assess insulin secretion and insulin sensitivity in primary aldosteronism (9).”
From Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans (2020) · cites this paper as [9]
In the citing paper
“However, the effects of hyperaldosteronism on insulin sensitivity and β-cell function are unclear.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [4]
In the citing paper
“Lastly, many of these studies were conducted in Europe or Japan [5,24,4,19,23] and thus not easily generalized to a more diverse and heterogenous US population.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [4]
In the citing paper
“Another study demonstrated an increased first-phase insulin response following unilateral adrenalectomy in nine PA patients, suggesting a direct negative effect of aldosterone on β-cell function [4].”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [4]
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,092
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
Cited by
Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
“3) (n = 155) 134 (19) (n = 126) 78 (12) (n = 126) 32/162 20% 13/162 8%”
Self-citationHanslik, G., Wallaschofski, H., Dietz, A., Riester, A., Reincke, M., Allolio, B., Lang, K., Quack, I., Rump, L. C., Willenberg, H. S., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0450 · Cited by 155
Self-citationSteroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Williams, T. A., & Reincke, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0990 · Cited by 141
Self-citationEffects of aldosterone on insulin sensitivity and secretion
Luther, J. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.08.016 · Cited by 114
“glucose-stimulated insulin secretion in patients with APA versus essential hypertension using frequently-sampled intravenous glucose tolerance tests, which improved after adrenalectomy (47).”
Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion
Gerards, J., Heinrich, D. A., Adolf, C., Meisinger, C., Rathmann, W., Sturm, L., Nirschl, N., Bidlingmaier, M., Beuschlein, F., Thorand, B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00299 · Cited by 112
Self-citationChen, S.-Y., Chen, J., Huang, W., Puar, T. H. K., Kek, P. C., Chueh, S., Lin, Y., Wu, V., & TAIPAI Study Group (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0375 · Cited by 78
Primary aldosteronism decreases insulin secretion and increases insulin clearance in humans
Adler, G. K., Murray, G. R., Turcu, A. F., Nian, H., Yu, C., Solorzano, C. C., Manning, R., Peng, D., & Luther, J. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13922 · Cited by 71
“In patients with aldosterone-producing adenomas, insulin secretion and disposition index (DI) assessed with intravenous glucose tolerance tests increase after adrenalectomy, suggesting that aldosterone impairs insulin secretion directly in humans.(9) Insulin sensitivity and secretion should ideally be determined separ…”
BackgroundResultRenin‐Angiotensin‐Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA
Joseph, J. J., Echouffo-Tcheugui, J. B., Effoe, V. S., Hsueh, W. A., Allison, M., & Golden, S. H. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009890 · Cited by 76
“The treatment of primary aldosteronism with adrenalectomy or mineralocorticoid receptor antagonism improves insulin sensitivity and insulin secretion.(27,28) The largest pharmacologic diabetes mellitus prevention trials examining RAAS antagonism as a primary end point, the DREAM (Diabetes Reduction Assessment with Ram…”
BackgroundHu, Q., Yin, L., & Hartmann, R. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401430e · Cited by 62
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
Muñoz‐Durango, N., Vecchiola, A., González-Gómez, L. M., Simón, F., Riedel, C. A., Fardella, C., & Kalergis, A. M. (2015) · BioMed Research International · doi:10.1155/2015/652738 · Cited by 68
“and bilateral idiopathic adrenal hyperplasia and causes excessive MR stimulation [98].”
BackgroundChen, W., Li, F., He, C., Zhu, Y., & Tan, W. (2014) · Irish Journal of Medical Science · doi:10.1007/s11845-013-1007-x · Cited by 53
The role of dietary salt in metabolism and energy balance: Insights beyond cardiovascular disease
Wu, Q., Burley, G., Li, L., Lin, S., & Shi, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14980 · Cited by 65
Aldosterone, Renin, and Diabetes Mellitus in African Americans: The Jackson Heart Study
Joseph, J. J., Echouffo-Tcheugui, J. B., Kalyani, R. R., Yeh, H.-C., Bertoni, A. G., Effoe, V. S., Casanova, R., Sims, M., Correa, A., Wu, W.-C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1002 · Cited by 51
“These findings were bolstered by a recent human study showing a significant improvement of the impaired firstphase insulin secretion ( -cell function) in patients with primary hyperaldosteronism after adrenalectomy (27).”
BackgroundLinks between aldosterone excess and metabolic complications: A comprehensive review
Bothou, C., Beuschlein, F., & Spyroglou, A. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.02.003 · Cited by 57
Self-citationCardiovascular risk in primary aldosteronism: A systematic review and meta-analysis
Wu, X., Yu, J., & Tian, H. (2019) · Medicine · doi:10.1097/md.0000000000015985 · Cited by 53
Hu, Y., Zhang, J., Liu, W., & Su, X. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz293 · Cited by 46
Prevalence, diagnosis and outcomes of treatment for primary aldosteronism
Yang, Y., Reincke, M., & Williams, T. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101365 · Cited by 43
Self-citationPharmacological treatment of aldosterone excess
Deinum, J., Riksen, N. P., & Lenders, J. W. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.006 · Cited by 45
Jin, H. M., Zhou, D. C., Gu, H. F., Qiao, Q. Y., Fu, S. K., Liu, X. L., & Pan, Y. (2013) · Endocrinology · doi:10.1210/en.2013-1115 · Cited by 40
“Recent studies demonstrate that higher levels of plasma aldosterone, a physiological ligand of the MR, precede the development of glucose intolerance and insulin resistance in patients with metabolic syndrome (5, 16, 17) and that aldosterone may directly interfere with insulin signaling by down-regulating insulin rece…”
BackgroundThe mineralocorticoid receptor—an emerging player in metabolic syndrome?
Thuzar, M., & Stowasser, M. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-020-00467-3 · Cited by 39
Tsurutani, Y., Sugisawa, C., Ishida, A., Inoue, K., Saito, J., Omura, M., Nagasaka, S., & Nishikawa, T. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0500 · Cited by 32
“showed that adrenalectomy for APA (n = 9) did not affect the index of insulin resistance, assessed using the insulin clamp method [7].”
BackgroundMethodInfluentialGlucose Metabolism in Primary Aldosteronism
Remde, H., Hanslik, G., Rayes, N., & Quinkler, M. O. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1565208 · Cited by 33
Worsening of lipid metabolism after successful treatment of primary aldosteronism
Adolf, C., Asbach, E., Dietz, A., Lang, K., Hahner, S., Quinkler, M. O., Rump, L. C., Bidlingmaier, M., Treitl, M., Ladurner, R., et al. (2016) · Endocrine · doi:10.1007/s12020-016-0983-9 · Cited by 31
“Both have been extensively documented by others and our own group [16, 23, 24].”
BackgroundMethodSelf-citationSecondary diabetes mellitus due to primary aldosteronism
Moustaki, M., Paschou, S. Α., Vakali, E., & Vryonidou, A. (2022) · Endocrine · doi:10.1007/s12020-022-03168-8 · Cited by 30
“This is in line with previous, prospective data demonstrating increased insulin resistance [7, 8] and impaired insulin secretion [9], as well as with recent, flash glucose monitoring system data, demonstrating increased general blood glucose levels, within-day and day-to-day glucose variability, incidence of hyperglyc…”
ResultLuther, J. M., Byrne, L. M., Yu, C., Wang, T. J., & Brown, N. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2122 · Cited by 26
Asbach, E., Bekeran, M., König, A., Lang, K., Hanslik, G., Treitl, M., Ladurner, R., Bidlingmaier, M., Beuschlein, F., Quinkler, M., et al. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1027-6472 · Cited by 25
“The diagnosis of PA was based on the guidelines of the Endocrine Society as described before [2, 17].”
MethodSelf-citationInoue, K., Kitamoto, T., Tsurutani, Y., Saito, J., Omura, M., & Nishikawa, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645488 · Cited by 28
Grasso, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0288-6 · Cited by 24
Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism
Grewal, S., Fosam, A., Chalk, L., Deven, A., Suzuki, M., Correa, R. R., Blau, J. E., Demidowich, A. P., Stratakis, C. A., & Muniyappa, R. (2021) · Endocrine · doi:10.1007/s12020-020-02576-y · Cited by 20
“The most common etiologies of excess aldosterone secretion are idiopathic hyperplasia or adenomas [3, 4].”
BackgroundInfluentialAldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats
Hofmann, A., Brunßen, C., Peitzsch, M., Martin, M., Mittag, J., Jannasch, A., Engelmann, F., Brown, N. F., Weldon, S. M., Huber, J., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1358 · Cited by 22
“Unilateral adrenalectomy restored first-phase insulin secretion (41).”
BackgroundIoakim, K. J., Sydney, G. I., & Paschou, S. Α. (2019) · HORMONES · doi:10.1007/s42000-019-00147-z · Cited by 20
Effects of Primary Aldosteronism and Different Therapeutic Modalities on Glucose Metabolism
Kwak, M. K., Lee, J. Y., Kim, B., Lee, S. H., & Koh, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122194 · Cited by 19
“Previous studies have suggested more beneficial effects of ADX than those of MRA therapy on glucose metabolism in PA [24,29,30] and increased insulin secretion after ADX [23,31] might support our speculation.”
BackgroundResultNayak, S. S., Amini‐Salehi, E., Joukar, F., Biswas, P., Nobakht, S., Letafatkar, N., Porteghali, P., Mohammadi‐Vajari, E., Mansour‐Ghanaei, F., Javid, M., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002048 · Cited by 19
“Elevated levels of aldosterone in individuals with PA disrupt insulin secretion in pancreatic beta cells [58] and promote insulin resistance in peripheral tissues [59] .”
Heinrich, D. A., Adolf, C., Quinkler, M. O., Holler, F., Lechner, B., Nirschl, N., Sturm, L., Görge, V., Beuschlein, F., & Reincke, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0138 · Cited by 21
Self-citationLoh, H. H., & Sukor, N. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0294-8 · Cited by 21
Okazaki‐Hada, M., Moriya, A., Nagao, M., Oikawa, S., Fukuda, I., & Sugihara, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13312 · Cited by 20
“Fischer et al.(32) also reported that the aldosterone excess in PA affects”
BackgroundGalati, S.-J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.010 · Cited by 23
Er, L., Lin, M.-C., Tsai, Y., Hsiao, J., Yang, C.-Y., Chang, C., Peng, K., Chueh, S., & Wu, V. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001153 · Cited by 18
Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure
Yang, Y., Reincke, M., & Williams, T. A. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0662-6081 · Cited by 19
“6/9 (67 %) 4/11 (36 %) 5/9 (56 %) NA 6 m [84]”
Self-citationAldosterone and type 2 diabetes mellitus
Zavatta, G., Casadio, E., Rinaldi, E., Pagotto, U., Pasquali, R., & Vicennati, V. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0065 · Cited by 18
Gendreitzig, P., Kunzel, H. E., Adolf, C., Handgriff, L., Müller, L., Holler, F., Sturm, L., Heinrich, D. A., Reincke, M., & Quinkler, M. O. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab099 · Cited by 18
“found in PA (8,9) leading to a higher prevalence of diabetes mellitus in PA patients (7,10).”
BackgroundSelf-citationPrimary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management
Pillai, P. R., Griffith, M. P., Schwarcz, M., & Weiss, I. A. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000281 · Cited by 19
“tion of hypokalemia with reduction in both plasma glucose and insulin levels with an increase in first-phase insulin secretion.(74) Two”
Evaluation of insulin sensitivity and secretion in primary aldosteronism
Watanabe, D., Yatabe, M., & Ichihara, A. (2016) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2016.1182176 · Cited by 16
“Additionally, it has been reported that aldosterone excess is related to a significant reduction in glucose-induced first-phase insulin secretion based on metabolic challenge tests (20).”
BackgroundWang, W., Wu, T.-H., Er, L., Huang, C., Tu, K., Fan, K., Tsai, C., Wang, S., Wu, C.-Y., Huang, S.-H., et al. (2024) · Hypertension Research · doi:10.1038/s41440-023-01538-x · Cited by 17
Pathophysiology, Diagnosis, and Treatment of Mineralocorticoid Disorders
Magill, S. B. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130042 · Cited by 17
“First phase insulin release was found to be significantly impaired during an intravenous glucose tolerance test in subjects with PA compared to normal controls and those with hypertension (92).”
Manosroi, W., Atthakomol, P., Watanawittawas, P., & Buranapin, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870047 · Cited by 17
“Twenty studies included data on FBG (2, 14, 25, 27, 28, 30, 32, 34–38, 40–47) with 10 studies excluded DM patients or discontinuing hypoglycemic agents before recruitment (25, 30, 36, 40–46), 7 on HbA1c (13, 25, 26, 30, 31, 36), 5 on 2-hr OGTT (25, 30, 32, 36, 47), 10 on HOMA-IR (25, 26, 28, 30, 33, 36, 41– 44), 5 on…”
Prevalence of Primary Aldosteronism in Newly Diagnosed Hypertensive Patients in Primary Care
Asbach, E., Kellnar, A., Bekeran, M., Schelling, J., Bidlingmaier, M., & Reincke, M. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1938-4242 · Cited by 15
Self-citationDaimon, M., KAMBA, A., Murakami, H., Mizushiri, S., Osonoi, S., Matsuki, K., Sato, E., Tanabe, J., Takayasu, S., Matsuhashi, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10815-y · Cited by 16
Komada, H., Hirota, Y., So, A., Nakamura, T., Okuno, Y., Fukuoka, H., Iguchi, G., Takahashi, Y., Sakaguchi, K., & Ogawa, W. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.002 · Cited by 15
Zhang, S.-L., Gao, J., Guo, Y., Feng, Q., Tang, J., Yan, L., Wang, J., Cheng, H., & Liu, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.547356 · Cited by 15
“Our results are also in agreement with previous studies in PA, which showed that an impairment of islet β-cell and first-phase insulin secretion was significantly improved after adrenalectomy (11, 36, 37).”
BackgroundResultAldosterone Excess and Resistant Hypertension: Investigation and Treatment
Stowasser, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0439-7 · Cited by 12
Han, M., Cao, X., Zhao, C., Yang, L., Yin, N., Shen, P., Zhang, J., Gao, F., Ren, Y., Liang, D., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.544752 · Cited by 10
Then, C., Ritzel, K., Herder, C., Then, H. L., Sujana, C., Heier, M., Meisinger, C., Peters, A., Köenig, W., Rathmann, W., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002558 · Cited by 9
“…for impaired glucose tolerance (IGT), since adrenalectomy reduced glucose and insulin values, 11 improved insulin sensitivity, 12 13 and restored a decreased first-phase insulin secretion in an intravenous glucose tolerance test 14 as well as the insulin response to a hyperglycemic clamp.”
BackgroundSelf-citationHigh Prevalence of Primary Aldosteronism in Patients with Type 2 Diabetes Mellitus and Hypertension
Tyfoxylou, E., Voulgaris, N., Gravvanis, C., Vlachou, S., Markou, Α., Papanastasiou, L., Tentolouris, N., Kassi, E. N., Kaltsas, G., Chrousos, G. P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092308 · Cited by 9
“Aldosterone excess also impairs the first phase of insulin secretion and may play a crucial role in systemic insulin resistance [5].”
BackgroundSun, K., Zhou, C., Gong, M., Zhang, Y., Jiang, Y., & Song, W. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14873 · Cited by 8
“In this study, several studies 20–24 The results of funnel plots for each outcome. hypoglycemic or lipid-lowering drugs, which was tough to divide into subgroups and had an impact on the results.”
BackgroundClinical Characteristics and Long-Term Outcome of Primary Aldosteronism in a Norwegian Population
Grytaas, M. A., Strømsøy, S., Rørvik, J. T., Arnes, J. B., Heie, A., Arnesen, T., Jørstad, M. D., Nedrebø, B. G., Jøssang, D. E., Jensen, D., et al. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-118909 · Cited by 9
Handgriff, L., Adolf, C., Heinrich, D. A., Braun, L., Nirschl, N., Sturm, L., Ladurner, R., Ricke, J., Seidensticker, M., Bidlingmaier, M., et al. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1164-1944 · Cited by 9
“Recently, emphasis has been made on the effects of glucocorticoid co-secretion in the setting of PA revealing a higher incidence of metabolic syndrome and type 2 diabetes mellitus due to impaired insulin secretion [7] and insulin-sensitivity [8] further worsening the cardiovascular and metabolic burden in PA.”
BackgroundSelf-citationZhu, Q., & Zhu, F. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14607 · Cited by 7
Castro, M. A., Paja, M., Peris, B. P., Boillos, M. G., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Ruiz-Sánchez, J. G., Delgado, A. V., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02090-8 · Cited by 7
Huang, X., Yu, S., Xiao, H., Pei, L., Chen, Y., Chen, W., Li, Y., Xiao, H., & Cao, X. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6685469 · Cited by 7
“In addition, in previous studies, the IVGTT (iv glucose tolerance test) showed that the first phase (0-10min) insulin response in the PA group was weaker than that in the EH group [19], which was consistent with our observation.”
BackgroundResultMansour, N., Brüdgam, D., Dischinger, U., Kürzinger, L., Adolf, C., Walter, R., Öcal, O., Schmidt, V. F., Rudolph, J., Ricke, J., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15013 · Cited by 9
“Recent studies have proven a broader metabolic influence of PA than previously suggested including impaired insulin ‐ secretion and sensitivity 3,4 and type 2 diabetes mellitus (T2DM) in PA patients.”
BackgroundSelf-citationPrimary aldosteronism long-term outcome: Medical versus surgical therapy
Schneider, H., Williams, T. A., Heinrich, D. A., Lechner, B., & Reincke, M. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.08.008 · Cited by 7
Self-citationScreening for primary aldosteronism in the diabetic population: a cohort study
Tan, S. J., Libianto, R., Yang, J., & Wong, J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15690 · Cited by 5
Mineralocorticoids, glucose homeostasis and type 2 diabetes mellitus: The Henan Rural Cohort study
Wei, D., Liu, X., Jiang, J., Tu, R., Qiao, D., Li, R., Wang, Y., Fan, M., Yang, X., Zhang, J., et al. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107558 · Cited by 5
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism
Tizianel, I., Madinelli, A., Crimì, F., Barbot, M., Censi, S., Sabbadin, C., & Ceccato, F. (2025) · Clinical Endocrinology · doi:10.1111/cen.15231 · Cited by 5
“The pathogenetic mechanisms of insulin resistance in PA are not entirely clarified yet; however, it seems that aldosterone exerts a role on insulin ‐ target tissues through genomic and non ‐ genomic effects via MR and glucocorticoid receptor (GR) [2, 4].”
Zhang, C., Jiang, Y., Su, T., Jiang, L., Zhou, W., Zhong, X., Wu, L., & Wang, W. (2022) · Endocrine · doi:10.1007/s12020-022-03095-8 · Cited by 4
“However, some other studies reported inconsistent or even opposite results [9, 10].”
ResultMansour, N., Brüdgam, D., Heinrich, D. A., Dischinger, U., Reisch, N., Völter, F., Stüfchen, I., Nowak, E., Zopp, S., Vasileva, V., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1521680 · Cited by 6
Self-citationConnshing syndrome – myth or reality?
Beuschlein, F. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.017 · Cited by 3
Self-citationAdolf, C., Berends, A. M. A., Connelly, M. A., Reincke, M., & Dullaart, R. P. F. (2020) · Endocrine · doi:10.1007/s12020-020-02235-2 · Cited by 3
“Remarkably, three recent studies have suggested that the plasma lipoprotein pro fi le may be worsened 1 year after unilateral ADX for PA [10 – 12].”
BackgroundResultInfluentialSelf-citationPrimary Aldosteronism: A Field on the Move
Doumas, M. N., & Δούμα, Σ. (2016) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-34141-5_2 · Cited by 3
Chu, W.-K., Er, L., Chang, C., Lu, J., Wu, W.-C., Tsai, Y., Lin, Y., & Wu, V. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241301892 · Cited by 2
“20 In patients with PA, excessive aldosterone has been associated with both impaired insulin secretion 21,22 and reduced insulin sensitivity.”
Association between serum uric acid levels and primary aldosteronism
Zhao, X., Jiao, H., Zhang, R., Zhao, H., Ma, L., Jia, Z., Tang, Z., & Gu, Y. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04504-6 · Cited by 2
“Metabolic syndrome is a concern for endocrinolo-gists, and several clinical studies have found that metabolic abnormalities such as hyperglycemia, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), and abdominal obesity are more frequent in patients with PA than in those with EH [13–15].”
The Relationship between Obesity, Insulin Resistance and Aldosterone Levels
Mazzuco, T. L. (2018) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2018.06.555680 · Cited by 1
“Aldosterone effects include direct action on pancreatic betacell mineralocorticoid receptors (MR), compromising their functional and structural integrity and reducing insulin release; induction of insulin resistance by the MR activation in adipose tissue; indirect effects related to hypokalemia states; and recent repo…”
BackgroundAdrenal Secretome and Epicardial Adipose Tissue
Petramala, L., Concistrè, A., Iannucci, G., & Letizia, C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-40570-0_14 · Cited by 1
Primary aldosteronism (Conn's syndrome)
Ceccato, F., Tizianel, I., Voltan, G., & Mantero, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96120-2.00014-5 · Cited by 2
Diabetes in Hyperaldosteronism
Crudo, V. L., Mulatero, P., Monticone, S., & Veglio, F. (2014) · Frontiers in diabetes · doi:10.1159/000357246
PRIMARY ALDOSTERONISM STUDIES ON SCREENING, OUTCOME OF ADRENALECTOMY AND FUNCTIONAL PATHOLOGY
Volpe, C. (2013) · Figshare
The Regulatory Effect of Renin-Angiotensin-Aldosterone System on Insulin Secretion *
Jia, Y., & Yang, B. (2013)
Primary aldosteronism as an endocrinological challenge – old doubts and new diagnostic possibilities
Cyrańska-Chyrek, E., Grzymisławska, M., & Ruchała, M. (2016) · Journal of Medical Science · doi:10.20883/jms.2016.104
The Regulatory Effect of Renin-Angiotensin-Aldosterone System on Insulin Secretion
贾, 英. (2013) · Biophysics · doi:10.12677/jps.2013.13003
Brunnenkant, L., Meng, Y., Sun, J., Júnior, J. G. M., Koletzko, B. V., y Schnitzler, M. M., Gudermann, T. W., Williams, T. A., Beuschlein, F., Heinrich, D. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.04.429624 · Cited by 1
Self-citationMetabolic effects of aldosterone
Валерьевна, И. К., Mazurina, N. V., Platonova, N. M., & Troshina, E. A. (2024) · Obesity and metabolism · doi:10.14341/omet13040 · Cited by 1
Ma, X., Lin, X., Liu, N., Zeng, Y., Guo, L., Feng, Q., Wu, M., Cai, F., Hu, Y., Wang, Y., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04492-5
“Emerging evidence has directly implicated PA in glucose metabolism dysregulation [ 6 ], with excessive aldosterone suppressing insulin secretion [ 7, 8 ] and inducing inflammation in adi - pose tissue [ 9 ], thereby inducing insulin resistance [ 10 ].”
Metadata
- Authors
- Fischer, E., Adolf, C., Pallauf, A., Then, C., Bidlingmaier, M., Beuschlein, F., Seissler, J., & Reincke, M.
- Affiliations
- LMU Klinikum (DE)
- Helmholtz Munich (DE)
- Medizinische Klinik and Poliklinik IV, Campus Innenstadt (E.F., C.A., A.P., C.T., M.B., F.B., J.S., M.R.), Klinikum der Universität München, 80336 München, Germany
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-06-01
- Volume
- 98
- Issue
- 6
- Pages
- 2513-2520
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1987584539
- Cited by
- 88
- References
- 57
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 9 · 2021: 6 · 2020: 10 · 2019: 13 · 2018: 7 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 8 · 2013: 5
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, aldosterone excess, beta-cell function, insulin sensitivity, adrenalectomy, aldosterone-producing adenoma, secondary hypertension, glucose metabolism
- MeSH terms
- Insulin Secretion, Adult, Aldosterone, Blood Glucose, Female, Humans, Hyperaldosteronism, Hypertension, Insulin, Male, Middle Aged, Prospective Studies, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.